Polypoidal regression is not cure: half of eyes recurred within two years off treatment

The edition in brief

In a prospective study at four Thai university hospitals, 81 treatment-naive eyes with polypoidal choroidal vasculopathy received three monthly aflibercept injections, with three more if polyps persisted. Of 26 eyes that reached complete regression and moved to as-needed treatment, half recurred within two years; a fifth of recurrences cost 10 or more letters and over a third brought new haemorrhage. Regression should prompt continued close OCT surveillance, not discharge or long gaps. The Swedish cataract register covered 979,534 operations from 2018 to 2024: endophthalmitis occurred in 0.013%, and rates with intracameral cefuroxime, cefuroxime plus ampicillin and moxifloxacin did not differ significantly, though enterococcal cases were commoner with cefuroxime alone. An Indian series of 29 patients with posterior segment metallic foreign bodies from chisel-and-hammer injuries found vitrectomy achieved anatomical success in about 90%, with mean vision improving from logMAR 2.4 to 1.2; delay between primary repair and vitrectomy was linked to worse vision. A German series of 12 patients with periorbital necrotising fasciitis linked older age and higher LRINEC scores to prolonged ICU care, and tissue-sparing debridement did not appear worse than radical surgery. The pearl: a hammering history means CT, not MRI.